The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
CD39/CD73 upregulation on myeloid-derived suppressor cells via TGF-β-mTOR-HIF-1 signaling in patients with non-small cell lung cancer
Open accessAbstract
CD39/CD73-adenosine pathway has been recently defined as an important tumor-induced immunosuppressive mechanism. We here documented a fraction of CD11b+CD33+ myeloid-derived suppressor cells (MDSCs) in peripheral blood and tumor tissues from non-small cell lung cancer (NSCLC) patients expressed surface ectonucleotidases CD39 and CD73. Tumor TGF-β stimulated CD39 and CD73 expression, thereby inhibited T cell and NK cell activity, and protected tumor cells from the cytotoxic effect of chemotherapy through ectonucleotidase activity. Mechanistically, TGF-β triggered phosphorylation of mammalian target of rapamycin, and subsequently activated hypoxia-inducible factor-1α (HIF-1α) that induced CD39/CD73 expression on MDSCs. CD39 and CD73 on MDSCs, therefore, link their immunosuppressive and chemo-protective effects to NSCLC progression, providing novel targets for chemo-immunotherapeutic intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Independent of glycolysis, the HIFs can induce the production of immunosuppressive metabolites such as adenosine by transcriptionally activating ectoenzymes such as ENTPD2/CD39L1, CD39, and CD73 (Table 1), which contribute to the multistep conversion of extracellular ATP through ADP/AMP to adenosine, thus promoting the maintenance of MDSCs, which limits the activity of immune checkpoint inhibitors”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [91]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
Deaglio, S., Dwyer, K. M., Gao, W., Friedman, D. J., Usheva, A., Erat, A., Chen, J., Enjyoji, K., Linden, J. M., Oukka, M., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062512 · Cited by 2,613
Immunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057
Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
Ostrand‐Rosenberg, S., & Sinha, P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802740 · Cited by 1,777
Immunosuppressive Strategies that are Mediated by Tumor Cells
Rabinovich, G. A., Gabrilovich, D. I., & Sotomayor, E. M. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,747
Kuang, D., Zhao, Q., Peng, C., Xu, J., Zhang, J., Wu, C. Y., & Zheng, L. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20082173 · Cited by 930
Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function
Condamine, T., & Gabrilovich, D. I. (2010) · Trends in Immunology · doi:10.1016/j.it.2010.10.002 · Cited by 857
Immune cell regulation by autocrine purinergic signalling
JUNGER, W. G. (2011) · Nature reviews. Immunology · doi:10.1038/nri2938 · Cited by 855
Zea, A. H., Rodrı́guez, P. C., Atkins, M. B., Hernandez, C., Signoretti, S., Zabaleta, J., McDermott, D. F., Quiceno, D. G., Youmans, A. J., O’Neill, A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4505 · Cited by 852
Cited by
Sorted by citations
Inflammation and tumor progression: signaling pathways and targeted intervention
Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00658-5 · Cited by 3,058
Self-citationHypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions
Chen, Z., Han, F., Du, Y., Shi, H., & Zhou, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01332-8 · Cited by 1,612
Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer
Li, K., Shi, H., Zhang, B., Ou, X., Ma, Q., Chen, Y., Shu, P., Li, D., & Wang, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00670-9 · Cited by 1,046
Self-citationImmunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression
Groth, C., Hu, X., Weber, R., Fleming, V., Altevogt, P., Utikal, J. S., & Umansky, V. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0333-1 · Cited by 871
Extracellular ATP and P2 purinergic signalling in the tumour microenvironment
Virgilio, F. D., Sarti, A. C., Falzoni, S., Marchi, E. D., & Adinolfi, E. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0037-0 · Cited by 748
Metabolic Regulation of Macrophage Polarization in Cancer
Mehla, K., & Singh, P. K. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.10.007 · Cited by 621
The adenosine pathway in immuno-oncology
Allard, B., Allard, D., Buisseret, L., & Stagg, J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0382-2 · Cited by 621
Targeting adenosine for cancer immunotherapy
Leone, R. D., & Emens, L. A. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0360-8 · Cited by 557
Myeloid-derived suppressor cells in cancer and cancer therapy
Lasser, S., Kurt, F. G. Ö., Arkhypov, I., Utikal, J. S., & Umansky, V. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00846-y · Cited by 523
Fates of CD8+ T cells in Tumor Microenvironment
Maimela, N. R., Liu, S., & Zhang, Y. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2018.11.004 · Cited by 459
Self-citationMyeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer
Law, A. M. K., Valdes-Mora, F., & Gallego-Ortega, D. (2020) · Cells · doi:10.3390/cells9030561 · Cited by 455
Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function
Viganó, S., Alatzoglou, D., Irving, M. B., Ménétrier‐Caux, C., Caux, C., Romero, P. J., & Coukos, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00925 · Cited by 434
Metabolic regulatory crosstalk between tumor microenvironment and tumor-associated macrophages
Chen, D., Zhang, X., Li, Z., & Zhu, B. (2021) · Theranostics · doi:10.7150/thno.51777 · Cited by 390
T Cell Dysfunction and Exhaustion in Cancer
Zhang, Z., Liu, S., Zhang, B., Qiao, L., Zhang, Y., & Zhang, Y. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00017 · Cited by 385
“Moreover, TGF-β stimulates CD39 and CD73 expression, thereby inhibiting autologous CD8+ T cell proliferation and function (Li et al., 2017).”
BackgroundSelf-citationReactive Oxygen Species as Regulators of MDSC-Mediated Immune Suppression
Ohl, K., & Tenbrock, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02499 · Cited by 340
Cicco, P. D., Ercolano, G., & Ianaro, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01680 · Cited by 341
Moesta, A. K., Li, X.-Y., & Smyth, M. J. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-020-0376-4 · Cited by 332
Hypoxia, Metabolic Reprogramming, and Drug Resistance in Liver Cancer
Bao, M. H.-R., & Wong, C. C.-L. (2021) · Cells · doi:10.3390/cells10071715 · Cited by 316
IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy
Weber, R., Groth, C., Lasser, S., Arkhypov, I., Petrova, V., Altevogt, P., Utikal, J. S., & Umansky, V. (2020) · Cellular Immunology · doi:10.1016/j.cellimm.2020.104254 · Cited by 317
Yang, Y., Li, C., Liu, T., Dai, X., & Bazhin, A. V. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01371 · Cited by 294
MDSCs: Key Criminals of Tumor Pre-metastatic Niche Formation
Wang, Y., Ding, Y., Guo, N., & Wang, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00172 · Cited by 289
The role of hypoxia‐inducible factor 1 in tumor immune evasion
Li, Y., Wu, W., Wang, X., Fang, L., Adam, V., Nepovimová, E., Wu, Q., & Kuča, K. (2020) · Medicinal Research Reviews · doi:10.1002/med.21771 · Cited by 276
Self-citationLi, L., Wang, L., Li, J., Fan, Z., Li, Y., Zhang, Z., Zhang, C., Yue, D., Qin, G., Zhang, T., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2460 · Cited by 267
Self-citationTGF-β signaling in the tumor metabolic microenvironment and targeted therapies
Shi, X., Yang, J., Deng, S., Xu, H., Wu, D., Zeng, Q., Wang, S., Hu, T., Wu, F., & Zhou, H. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01349-6 · Cited by 262
Genova, C., Dellepiane, C., Carrega, P., Sommariva, S., Ferlazzo, G., Pronzato, P., Gangemi, R. M. R., Filaci, G., Coco, S., & Croce, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.799455 · Cited by 273
How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer
Stultz, J., & Fong, L. (2021) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-021-00340-5 · Cited by 242
Breast cancer-derived exosomes transmit lncRNA SNHG16 to induce CD73+γδ1 Treg cells
Ni, C., Fang, Q.-Q., Chen, W., Jiang, J.-X., Zhou, J., Ye, J., Zhang, T., Yang, L., Meng, F.-B., Xia, W.-J., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0129-7 · Cited by 246
Self-citationATP and cancer immunosurveillance
Kepp, O., Bezu, L., Yamazaki, T., Virgilio, F. D., Smyth, M. J., Kroemer, G., & Galluzzi, L. (2021) · The EMBO Journal · doi:10.15252/embj.2021108130 · Cited by 238
mTOR-Mediated Regulation of Immune Responses in Cancer and Tumor Microenvironment
Mafi, S., Mansoori, B., Taeb, S., Sadeghi, H., Abbasi, R., Cho, W. C. S., & Rostamzadeh, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.774103 · Cited by 238
The role of tumor-associated macrophages in tumor immune evasion
Huang, R., Kang, T., & Chen, S. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05777-4 · Cited by 230
Gao, Q., Wang, S., Chen, X., Cheng, S., Zhang, Z., Li, F., Huang, L. J., Yang, Y., Zhou, B., Yue, D., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0511-6 · Cited by 222
Self-citationHypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma
Daniel, S. K., Sullivan, K. M., Labadie, K. P., & Pillarisetty, V. G. (2019) · Clinical and Translational Medicine · doi:10.1186/s40169-019-0226-9 · Cited by 215
NK cells and solid tumors: therapeutic potential and persisting obstacles
Tong, L., Jiménez‐Cortegana, C., Tay, A. H. M., Wickström, S. L., Galluzzi, L., & Lundqvist, A. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01672-z · Cited by 197
Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy
Liu, Z., Zhou, Z., Dang, Q., Xu, H. M., Lv, J., Li, H., & Han, X. (2022) · Theranostics · doi:10.7150/thno.76854 · Cited by 200
Self-citationMyeloid-derived suppressor cells—new and exciting players in lung cancer
Yang, Z., Guo, J., Weng, L., Tang, W., Jin, S., & Ma, W. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-0843-1 · Cited by 191
ATP and Adenosine Metabolism in Cancer: Exploitation for Therapeutic Gain
Yegutkin, G. G., & Boison, D. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000528 · Cited by 179
Targeting CD73 to augment cancer immunotherapy
Roh, M., Wainwright, D. A., Wu, J. D., Wan, Y., & Zhang, B. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.07.001 · Cited by 165
Self-citationTargeting the CD73-adenosine axis in immuno-oncology
Allard, D., Chrobák, P., Allard, B., Messaoudi, N., & Stagg, J. (2018) · Immunology Letters · doi:10.1016/j.imlet.2018.05.001 · Cited by 161
Metabolic reprogramming and immune evasion: the interplay in the tumor microenvironment
Zhang, H., Li, S., Wang, D., Liu, S. M., Xiao, T., Gu, W., Yang, H., Wang, H. Z., Yang, M., & Chen, P. (2024) · Biomarker Research · doi:10.1186/s40364-024-00646-1 · Cited by 178
Antuamwine, B. B., Bosnjakovic, R., Hofmann-Vega, F., Wang, X., Θεοδοσίου, Θ., Iliopoulos, I., & Brandau, S. (2022) · Immunological Reviews · doi:10.1111/imr.13176 · Cited by 160
Hypoxia-Driven Effects in Cancer: Characterization, Mechanisms, and Therapeutic Implications
Shi, R., Liao, C., & Zhang, Q. H. (2021) · Cells · doi:10.3390/cells10030678 · Cited by 151
Transforming Growth Factor-β: A Multifunctional Regulator of Cancer Immunity
Xue, V. W., Chung, J. Y., Córdoba, C. A. G., Cheung, A. H. K., Kang, W., Lam, E. W. ‐., Leung, K. T., To, K., Lan, H. Y., & Tang, P. M. (2020) · Cancers · doi:10.3390/cancers12113099 · Cited by 154
Cd73: An Emerging Checkpoint for Cancer Immunotherapy
Chen, S., Wainwright, D. A., Wu, J. D., Wan, Y., Matei, D. E., Zhang, Y., & Zhang, B. (2019) · Immunotherapy · doi:10.2217/imt-2018-0200 · Cited by 154
Self-citationOn the mechanism of anti-CD39 immune checkpoint therapy
Allard, D., Allard, B., & Stagg, J. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000186 · Cited by 136
Role of mTOR Signaling in Tumor Microenvironment: An Overview
Conciatori, F., Bazzichetto, C., Falcone, I., Pilotto, S., Bria, E., Cognetti, F., Milella, M., & Ciuffreda, L. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082453 · Cited by 131
Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy
Augustin, R. C., Leone, R. D., Naing, A., Fong, L. H., Bao, R., & Luke, J. J. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004089 · Cited by 131
Salminen, A., Kauppinen, A., & Kaarniranta, K. (2019) · Journal of Molecular Medicine · doi:10.1007/s00109-019-01795-9 · Cited by 122
Hepatic Tumor Microenvironments and Effects on NK Cell Phenotype and Function
Fernández, J. P., Luddy, K. A., Harmon, C., & O’Farrelly, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174131 · Cited by 119
Yu, Q., Xia, Y., Lin, Z., Qu, Y., Qi, Y., Chen, Y., Zhou, Q., Zeng, H., Wang, J., Chang, Y., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02563-2 · Cited by 118
Myeloid-Derived Suppressor Cells: Ductile Targets in Disease
Consonni, F. M., Porta, C., Marino, A., Pandolfo, C., Mola, S., Bleve, A., & Sica, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00949 · Cited by 110
Kurt, F. G. Ö., Lasser, S., Arkhypov, I., Utikal, J. S., & Umansky, V. (2023) · Journal of Clinical Investigation · doi:10.1172/jci170762 · Cited by 111
Targeting myeloid-derived suppressor cells for cancer immunotherapy
Liu, Y., Wei, G., Cheng, W. A., Dong, Z., Sun, H., Lee, V. Y., Cha, S.-C., Smith, D. L., Kwak, L. W., & Qin, H. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2175-3 · Cited by 110
Hasan, M. M., Thompson-Snipes, L., Klintmalm, G. B., Demetris, A. J., O’Leary, J. G., Oh, S., & Joo, H. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1900488 · Cited by 112
Tomić, S., Joksimović, B., Bekić, M., Vasiljević, M., Milanović, M., Čolić, M. J., & Vučević, D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00475 · Cited by 106
The impact of hypoxia on immune state in cancer
Mortezaee, K., & Majidpoor, J. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.120057 · Cited by 102
Chen, S., Fan, J., Zhang, M., Qin, L., Dominguez, D., Long, A., Wang, G., Ma, R., Li, H., Zhang, Y., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08123-8 · Cited by 98
Self-citationChambers, A. M., & Matosevic, S. (2019) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2019.00060 · Cited by 100
Purinergic Signaling in the Hallmarks of Cancer
Campos‐Contreras, A. D. R., Díaz‐Muñoz, M., & Vázquez‐Cuevas, F. G. (2020) · Cells · doi:10.3390/cells9071612 · Cited by 103
Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy
Hao, Z., Li, R., Wang, Y., Li, S., Hong, Z., & Han, Z. (2021) · Biomarker Research · doi:10.1186/s40364-021-00333-5 · Cited by 101
Overcoming tumor resistance mechanisms in CAR-NK cell therapy
Valeri, A., García-Ortiz, A., Castellano, E., Córdoba, L., Maroto-Martín, E., Encinas, J., Leivas, A., Río, P., & Martínez‐López, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.953849 · Cited by 96
Metformin blocks myeloid-derived suppressor cell accumulation through AMPK-DACH1-CXCL1 axis
Qin, G., Lian, J., Huang, L. J., Zhao, Q., Liu, S., Zhang, Z., Chen, X., Yue, D., Li, L., Li, F., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1442167 · Cited by 94
Self-citationTargeting the Immunomodulatory CD73/Adenosine System to Improve the Therapeutic Gain of Radiotherapy
de Leve, S., Wirsdörfer, F., & Jendrossek, V. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00698 · Cited by 93
Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment
Ziogas, D. C., Theocharopoulos, C., Lialios, P., Foteinou, D., Koumprentziotis, I., Xynos, G., & Gogas, H. J. (2023) · Cancers · doi:10.3390/cancers15102718 · Cited by 95
Liu, C.-M., Yang, L., Xu, H.-Y., Zheng, S.-F., Wang, Z.-Y., Wang, S., Yang, Y.-N., Zhang, S.-Y., Feng, X., Sun, N., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02356-7 · Cited by 85
Self-citationLarge-scale analysis reveals the specific clinical and immune features of B7-H3 in glioma
Zhang, C., Zhang, Z., Li, F., Shen, Z., Qiao, Y., Li, L., Liu, S., Song, M., Zhao, X., Ren, F., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1461304 · Cited by 91
Self-citationCanonical and non-canonical adenosinergic pathways
Ferretti, E., Horenstein, A. L., Canzonetta, C., Costa, F., & Morandi, F. (2018) · Immunology Letters · doi:10.1016/j.imlet.2018.03.007 · Cited by 92
CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers
Harvey, J. B., Phan, L. H., Villarreal, O. E., & Bowser, J. L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00508 · Cited by 88
Targeting purine metabolism in ovarian cancer
Liu, J., Hong, S., Jiang, Y., Zhang, X., Wang, Y., Wang, H., Peng, J., & Hong, L. (2022) · Journal of Ovarian Research · doi:10.1186/s13048-022-01022-z · Cited by 93
Hsu, S., Cheng, K., Mgbeahuruike, M. O., Lin, Y., Wu, C., Wang, H., Yen, C., Chiu, C., & Sheu, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179453 · Cited by 83
Interaction Between MDSC and NK Cells in Solid and Hematological Malignancies: Impact on HSCT
Tumino, N., Pace, A. L. D., Besi, F., Quatrini, L., Vacca, P., & Moretta, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.638841 · Cited by 84
Implication of TIGIT+ human memory B cells in immune regulation
Hasan, M. M., Nair, S. S., O’Leary, J. G., Thompson-Snipes, L., Nyarige, V., Wang, J., Park, W. D., Stegall, M. D., Heilman, R. L., Klintmalm, G. B. G., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21413-y · Cited by 82
Wu, L., Xie, W., Li, Y., Ni, Q., Timashev, P. S., Lyu, M., Xia, L., Zhang, Y., Liu, L., Yuan, Y., et al. (2022) · Advanced Science · doi:10.1002/advs.202105376 · Cited by 87
Self-citationThe Synergistic Cooperation between TGF-β and Hypoxia in Cancer and Fibrosis
Mallikarjuna, P., Zhou, Y., & Landström, M. (2022) · Biomolecules · doi:10.3390/biom12050635 · Cited by 84
Adenosine Blockage in Tumor Microenvironment and Improvement of Cancer Immunotherapy
Arab, S., & Hadjati, J. (2019) · Immune Network · doi:10.4110/in.2019.19.e23 · Cited by 87
Immunotherapy of targeting MDSCs in tumor microenvironment
Sui, H., Dongye, S., Liu, X., Xu, X., Wang, L., Jin, C. Q., Yao, M., Gong, Z., Jiang, D., Zhang, K., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.990463 · Cited by 82
Self-citationMDSC in Mice and Men: Mechanisms of Immunosuppression in Cancer
Vanhaver, C., van der Bruggen, P., & Bruger, A. M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10132872 · Cited by 77
Adenosine in cancer immunotherapy: Taking off on a new plane
Zhang, C., Wang, K., & Wang, H. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.189005 · Cited by 82
Targeting purinergic pathway to enhance radiotherapy-induced immunogenic cancer cell death
Bao, X., & Xie, L. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02430-1 · Cited by 76
Autoimmunity and Cancer—Two Sides of the Same Coin
Sakowska, J., Arcimowicz, Ł., Jankowiak, M., Papak, I., Markiewicz, A., Dziubek, K., Kurkowiak, M., Kote, S., Kaźmierczak-Siedlecka, K., Połom, K., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.793234 · Cited by 80
The Engagement Between MDSCs and Metastases: Partners in Crime
Trovato, R., Canè, S., Petrova, V., Sartoris, S., Ugel, S., & Sanctis, F. D. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00165 · Cited by 74
The elegant complexity of mammalian ecto-5′-nucleotidase (CD73)
Alcedo, K. P., Bowser, J. L., & Snider, N. T. (2021) · Trends in Cell Biology · doi:10.1016/j.tcb.2021.05.008 · Cited by 72
Giatromanolaki, A. N., Kouroupi, M., Pouliliou, S., Mitrakas, A. G., Hasan, F., Pappa, A., & Koukourakis, M. I. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118389 · Cited by 71
Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy
Chrétien, S., Zerdes, I., Bergh, J. C. S., Matikas, A., & Foukakis, T. (2019) · Cancers · doi:10.3390/cancers11050628 · Cited by 71
Metabolic Regulation of Myeloid-Derived Suppressor Cell Function in Cancer
Wang, Y., Jia, A., Bi, Y., Wang, Y., & Liu, G. (2020) · Cells · doi:10.3390/cells9041011 · Cited by 73
Antigen presentation, autoantibody production, and therapeutic targets in autoimmune liver disease
Horst, A. K., Kumashie, K. G., Neumann, K., Diehl, L., & Tiegs, G. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00568-6 · Cited by 73
The Clinical Significance of CD73 in Cancer
Bach, N., Winzer, R., Tolosa, E., Fiedler, W., & Brauneck, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411759 · Cited by 74
Nanotechnology Reprogramming Metabolism for Enhanced Tumor Immunotherapy
Zhou, Y., Yuan, J. T., Xu, K., Li, S., & Liu, Y. (2024) · ACS Nano · doi:10.1021/acsnano.3c11260 · Cited by 73
TGF-β in Cancer: Metabolic Driver of the Tolerogenic Crosstalk in the Tumor Microenvironment
Angioni, R., Sánchez‐Rodríguez, R., Viola, A., & Molon, B. (2021) · Cancers · doi:10.3390/cancers13030401 · Cited by 73
Cancer immune exclusion: breaking the barricade for a successful immunotherapy
Bruni, S., Mercogliano, M. F., Mauro, F. L., Russo, R. I. C., & Schillaci, R. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1135456 · Cited by 72
The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation
Acuña-Pilarte, K., & Koh, M. Y. (2025) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2025.06.005 · Cited by 64
Regulation of immune responses through CD39 and CD73 in cancer: Novel checkpoints
Baghbani, E., Noorolyai, S., Shanehbandi, D., Mokhtarzadeh, A., Maleki, L. A., Khaze, V., Brunetti, O., Rahmani, S., Shadbad, M. A., Baghbanzadeh, A., et al. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119826 · Cited by 64
Lakshmanachetty, S., Cruz, J. C., Hoffmeyer, E., Cole, A. P., & Mitra, S. S. (2021) · Cells · doi:10.3390/cells10040893 · Cited by 62
Hofer, F., Sario, G. D., Musiu, C., Sartoris, S., Sanctis, F. D., & Ugel, S. (2021) · Cells · doi:10.3390/cells10102700 · Cited by 64
Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity
Kashyap, A. S., Thelemann, T., Klar, R., Kallert, S. M., Festag, J., Buchi, M., Hinterwimmer, L., Schell, M., Michel, S., Jaschinski, F., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0545-9 · Cited by 60
OXPHOS inhibitors, metabolism and targeted therapies in cancer
Cadassou, O., & Jordheim, L. P. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115531 · Cited by 59
Review immune response of targeting CD39 in cancer
Liu, Y., Li, Z., Zhao, X., Xiao, J., Bi, J., Li, X.-Y., Chen, G., & Lu, L. (2023) · Biomarker Research · doi:10.1186/s40364-023-00500-w · Cited by 59
Self-citationCD39 – A bright target for cancer immunotherapy
Guo, S., Han, F., & Zhu, W. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113066 · Cited by 57
Tumino, N., Besi, F., Martini, S., Pace, A. L. D., Munari, E., Quatrini, L., Pelosi, A., Fiore, P. F., Fiscon, G., Paci, P., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.803014 · Cited by 58
Pfefferle, A., Jacobs, B., Netskar, H., Ask, E. H., Lorenz, S., Clancy, T., Goodridge, J. P., Sohlberg, E., & Malmberg, K. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.058 · Cited by 61
Hypoxia-Regulated Tumor-Derived Exosomes and Tumor Progression: A Focus on Immune Evasion
Shao, X., Hua, S., Feng, T., Ocansey, D. K. W., & Yin, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911789 · Cited by 60
Metadata
- Authors
- Li, J., Wang, L., Chen, X., Li, L., Li, Y., Ping, Y., Huang, L., Yue, D., Zhang, Z., Wang, F., Li, F., Yang, L., Huang, J., Yang, S., Li, H., Zhao, X., Dong, W., Yan, Y., Zhao, S., Huang, B., Zhang, B., & Zhang, Y.
- Affiliations
- First Affiliated Hospital of Zhengzhou University (CN)
- Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
- Biotherapy Center, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Northwestern University (US)
- Corresponding author
- Wang, Liping
- Zhang, Bin
- Zhang, Yi
- ORCID
- Venue
- OncoImmunology
- Publisher
- Informa UK Limited
- Published
- 2017-05-30
- Volume
- 6
- Issue
- 6
- Pages
- e1320011-e1320011
- ISSN
- 2162-4011 (ISSN-L)
- 2162-402X
- PMC
- PMC5486179
- OpenAlex
- W2605835842
- Cited by
- 299
- References
- 57
- Citations by year
- 2026: 22 · 2025: 32 · 2024: 33 · 2023: 33 · 2022: 52 · 2021: 45 · 2020: 37 · 2019: 26 · 2018: 19
- FWCI
- 17.23
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- OncoImmunology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (81171985, 112300410153, 122300410155, 81171986, 20110110001)
- Science and Technology Department of Henan Province
- National Institutes of Health (CA149669)
- National Cancer Institute (R01CA208354)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Adenosine and Purinergic Signaling
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Keywords
- CD39/CD73, myeloid-derived suppressor cells, non-small cell lung cancer, TGF-beta, mTOR, HIF-1α, adenosine pathway, ectonucleotidases, tumor immunosuppression, chemoresistance, T cell suppression, NK cell inhibition, chemoimmunotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
